OrganoTherapeutics

OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinsons disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinsons disease pathology. OrganoTherapeutics aims at developing new drug candidates against Parkinsons disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.